- Home
- GALT
as of 12-31-2025 3:53pm EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 261.1M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 813.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $7.13 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GALT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
Director
Avg Cost/Share
$3.55
Shares
5,500
Total Value
$19,514.00
Owned After
55,269
SEC Form 4
Director
Avg Cost/Share
$3.73
Shares
1,400
Total Value
$5,222.00
Owned After
65,382
President and CEO
Avg Cost/Share
$7.06
Shares
7,829
Total Value
$55,241.42
Owned After
832,592
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.04
Shares
19,442
Total Value
$136,871.68
Owned After
0
Director
Avg Cost/Share
$7.04
Shares
24,499
Total Value
$172,423.96
Owned After
6,500
10% Owner
Avg Cost/Share
$6.66
Shares
30,681
Total Value
$204,335.46
Owned After
5,614,457
SEC Form 4
Director
Avg Cost/Share
$6.30
Shares
8,417
Total Value
$53,027.10
Owned After
6,500
SEC Form 4
Director
Avg Cost/Share
$6.27
Shares
19,793
Total Value
$124,181.28
Owned After
6,500
SEC Form 4
Director
Avg Cost/Share
$6.27
Shares
16,790
Total Value
$105,206.14
Owned After
6,500
SEC Form 4
Director
Avg Cost/Share
$5.98
Shares
159,000
Total Value
$950,105.00
Owned After
6,500
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | GALT | Director | Dec 23, 2025 | Buy | $3.55 | 5,500 | $19,514.00 | 55,269 | |
| ELDRED KARY | GALT | Director | Dec 23, 2025 | Buy | $3.73 | 1,400 | $5,222.00 | 65,382 | |
| LEWIS JOEL | GALT | President and CEO | Dec 17, 2025 | Sell | $7.06 | 7,829 | $55,241.42 | 832,592 | |
| Jamil Khurram | GALT | Chief Medical Officer | Dec 17, 2025 | Sell | $7.04 | 19,442 | $136,871.68 | 0 | |
| Shlevin Harold H. | GALT | Director | Dec 17, 2025 | Sell | $7.04 | 24,499 | $172,423.96 | 6,500 | |
| 10X Fund, L.P. | GALT | 10% Owner | Dec 16, 2025 | Sell | $6.66 | 30,681 | $204,335.46 | 5,614,457 | |
| Shlevin Harold H. | GALT | Director | Dec 15, 2025 | Sell | $6.30 | 8,417 | $53,027.10 | 6,500 | |
| Shlevin Harold H. | GALT | Director | Dec 12, 2025 | Sell | $6.27 | 19,793 | $124,181.28 | 6,500 | |
| Shlevin Harold H. | GALT | Director | Dec 9, 2025 | Sell | $6.27 | 16,790 | $105,206.14 | 6,500 | |
| Shlevin Harold H. | GALT | Director | Dec 8, 2025 | Sell | $5.98 | 159,000 | $950,105.00 | 6,500 |
Compare GALT vs Leading Stocks
See how GALT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.